Millie
your market intelligence analyst
Search Results
Edit Save
274 results
Novartis International AG 08/19/2019 01:15
PARAGON-HF trial will provide Entresto ® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF) [1]. New PROVE-HF and EVALUATE-HF studies will highlight Entresto’s direct impact on the heart in heart failure with reduced ejection fraction (HFrEF) [2][3]. New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilization [4][5][6][7]. Basel, August 19, ...
Novartis International AG 08/15/2019 10:13
The “Flexibility at Novartis” series spotlights associates who have one thing in common: They work flexibly. As a result, they are able to manage the demands of their work and private lives. Flexible working can boost employee engagement while increasing efficiency and productivity. This series provides a glimpse into flexible working at Novartis. Shamsah Kazani is Director of Translational Medicine at the Novartis Institutes for BioMedical Research (NIBR) in Cambridge, Massachusetts, in the US. She shares her story below. Turning anguish into harmony, through flexibility ...
Novartis International AG 08/09/2019 15:46
Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit. Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases. Sandoz remains deeply committed to providing Erelzi ® as soon as possible, contributing to a more sustainable healthcare system. Holzkirchen, Germany, 9 August 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States ...
Novartis International AG 08/07/2019 11:41
In case you missed it, the Three-Eyed Raven is a character on the TV series “Game of Thrones” that can see the past, present and future. It also happens to be the pet name of a microscope at the Novartis Institutes for BioMedical Research (NIBR). A super-resolution microscope. One of its jobs is to help Novartis drug hunters understand the past, present and future of brain cells destroyed by Alzheimer’s disease. Super-resolution microscopy does exactly what the name implies: It gives super powers to light microscopes, which enable scientists to see small things such as cells. ...
Novartis International AG 08/05/2019 04:00
Matters of the heart. The heart, and how to fix it when it is no longer working, has been an important area for us at Novartis. It has been the focus of our research and commitment, where we’ve won awards, where we are striving forwards in the discovery of new management options, and most importantly where we have seen the huge impact of our work on the lives of patients. According to the World Health Organization, cardiovascular disease is the number one cause of death globally 1 . Eclipsing starvation and infectious diseases as the most critical health concern, ...
Novartis International AG 07/29/2019 12:05
Dimitris Agrafiotis describes himself as addicted to innovation. He got his start as a chemist, but computer technology played to his natural strengths – and one particular weakness. “I have a bad memory,” he says. Growing up, Agrafiotis – now Chief Information Officer (CIO) of the Novartis Institutes for BioMedical Research (NIBR) – wasn’t particularly good at memorizing facts, but he had an active imagination. He found computer science appealing because it uses relatively few foundational rules but offers limitless possibilities for an imaginative mind. ...
Novartis International AG 07/29/2019 01:05
PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed. Totality of evidence suggests potential clinically important benefit; results will be presented in September at the ESC Congress 2019, the annual meeting of the European Society of Cardiology (ESC). Novartis plans to engage in conversations with clinical experts and regulators on next steps. Basel, July 29, 2019 - Novartis today announced topline results from the global Phase III ...
Novartis International AG 07/26/2019 08:21
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants. Positive opinion is based on the landmark Phase III RAINBOW trial, which showed that Lucentis (ranibizumab) is an efficacious, safe and well-tolerated treatment for infants with ROP[1]. Standard of care treatment for ROP, laser surgery, destroys diseased retinal tissue responsible for elevated vascular endothelial growth factor (VEGF) whereas injectable Lucentis is a ...
Novartis International AG 07/25/2019 12:00
Elena leads Diversity & Inclusion (D&I) at Novartis, with a focus on increasing diversity of talent, strengthening inclusive behaviors and influencing positive change in society. A bioorganic chemist by training, she spent most of her career in drug research and development, and was instrumental in growing a small US technology institute into a drug discovery engine for Novartis. Elena, you spent most of your career in Research & Development, what made you decide to lead Diversity & Inclusion at Novartis? D&I has been a constant theme in my life. Growing ...
Novartis International AG 07/25/2019 04:00
It was another hard day for the Novartis team in Stein, Switzerland, but not because of the bad weather, which had taken an unexpected turn for the worse in mid-March. For eight hours, they were training intensively, as they had been for the weeks and months before - hardwiring the myriad steps that their new job would soon require them to do faultlessly every day. Exercising either in pairs, with one colleague verifying every move made by his or her peer, or under the supervision of ...
Novartis International AG 07/22/2019 18:13
The “Flexibility at Novartis” series spotlights associates who have one thing in common: They work flexibly. As a result, they are able to manage the demands of their work and private lives. Flexible working can boost employee engagement while increasing efficiency and productivity. This series provides a glimpse into flexible working at Novartis. Linda Karpiak supports the Kymriah® Managed Access Program and clinical trials as a Clinical Research Manager in East Hanover, New Jersey, in the US. She shares her story below. Balancing my priorities at work and at home. I ...
Novartis International AG 07/22/2019 01:20
Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1]. Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures -- number set to increase substantially over next two decades[2]. Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab. Holzkirchen, July 22, 2019 - Sandoz, a Novartis division and a ...
Novartis International AG 07/18/2019 01:05
Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by:. Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%). Entresto grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulatory settings. Oncology sales grew 9% (cc) driven by growth from Lutathera (USD 109 million), Kisqali (USD 111 million) and Kymriah (USD 58 million) in the second quarter. Sandoz sales grew 3% (cc, -1% USD) as ex-US growth more ...
Novartis International AG 07/09/2019 09:50
The “Flexibility at Novartis” series spotlights associates who have one thing in common: They work flexibly. As a result, they are able to manage the demands of their work and private lives. Flexible working can boost employee engagement while increasing efficiency and productivity. This series provides a glimpse into flexible working at Novartis. Janneke van der Kamp serves as Global Head Pharma, Region Europe, in Basel, Switzerland. She shares her story below. Leading by example. My flexibility story is really many stories, and they are not only about me. When I ...
Novartis International AG 07/08/2019 09:30
Novartis has transformed its Global Health & Corporate Responsibility (GH&CR) organization. The change consolidates and streamlines expertise and resources to achieve a stronger focus on the areas where the company can have the greatest impact. “This transformation is yet another demonstration of our unwavering commitment to place global health and corporate responsibility at the core of our business strategy,” said Patrice Matchaba, Group Head, Global Health & Corporate Responsibility. The new GH&CR organization will oversee end-to-end execution of the company ...
Novartis International AG 07/02/2019 01:35
Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1]. More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourth most common cancer[2]. With launch Sandoz builds on robust 50+ medicine oncology portfolio globally, including chemotherapy, targeted therapy, hormones and supportive care[3]. Holzkirchen, Germany, July 2, 2019 - Sandoz today announced the launch of the ...
Novartis International AG 07/02/2019 01:20
Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary progressive MS (SPMS) patients, supporting the use of blood NfL levels as a biomarker[1]. EXPAND data previously presented demonstrated Mayzent® (siponimod) has a meaningful benefit on cognitive processing speed with a 22.6% relative risk reduction versus placebo in SPMS patients with cognitive impairment[2]. In addition, EXPAND ...
Novartis International AG 07/01/2019 11:34
Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease[1]. Marie-France Tschudin, President, Novartis Pharmaceuticals, said: "This deal delivers on our ongoing commitment to reimagine medicine for patients suffering from a variety of eye diseases, while also laying critical groundwork for future, potential front-of-the-eye pipeline products we have in ...

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications